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Severe Fever with Thrombocytopenia Syndrome virus (SFTSV) is 
an emerging tick-borne virus which causes SFTS disease with a 
mortality rate of 5-27% in humans. Despite the high mortality 
rate of SFTS, no effective vaccine or therapy is available yet. 
Here, I have developed DNA encoding of SFTSV genes fused with 
FMS-like tyrosine kinase-3 ligand (Flt3L) at N-terminus and 
IL-12 genes which can stimulate cell-mediated adaptive immunity. 
Vaccination of the recombinant DNA conferred complete 
protection of interferon-α/β receptor knock-out (IFNAR K/O) mice 
against a lethal dose of SFTSV. Although I failed to observe a 
neutralizing antibody response, antigen-specific T cell responses 
were significantly increased in the immunized mice. The degree of 
protective immunity elicited by the immunization of various 
subunits (Gn, Gc, and NP) of SFTSV in a single subunit form or 
combinatorial formulation was also investigated. Vaccination of a 
single recombinant protein, NP or Gn, provided approximately 50% 
protection in IFNAR K/O mice upon lethal infection with SFTSV, 
whereas immunization of Gc protein failed to protect the 
challenged mice. Interestingly, immunization with NP showed 
enhanced antigen-specific T cell responses and Gc vaccination 
provided strong neutralizing activity against SFTSV. Finally, 
IFNAR K/O mice were immunized with a mixture of SFTSV 
proteins (Gn+NP, Gc+NP, and Gn+Gc+NP). Among these groups, 
Gc+NP immunization conferred the best (approximately 90%) 
protection against a lethal SFTSV infection when compared to 
those of other groups (Gn+NP: 70%, and Gn+Gc+NP: 57%) and 
this might be due to an enhanced T cell response and increased 
neutralizing activity against SFTSV. Collectively, vaccination with 
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DNA encoding SFTSV subunit genes or with combinatorial SFTSV 
subunits, including NP and Gc, could be a promising candidate for 
protection against SFTSV infection.
*This work is published in PLOS Neglected Tropical Diseases (Kang,
J. G., Jeon, K., Choi, H., Kim, Y., Kim, H. I., Ro, H. J., ... & Kim, Y.
S. (2020). Vaccination with single plasmid DNA encoding IL-12 and
antigens of severe fever with thrombocytopenia syndrome virus elicits
complete protection in IFNAR knockout mice. PLoS neglected tropical
diseases, 14(3), e0007813).
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Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) is
an emerging tick-borne arbovirus, included in the Phenuiviridae
family of Bunyavirales order [4, 5]. SFTSV is a spherical shaped
virion of about 100nm in diameter [6, 7]. This virus has three
different segments of ambisense or negative sense RNAs: Large (L),
Medium (M), and Small (S). Each segment encodes the
RNA-dependent RNA polymerase (L segment), the envelop
glycoproteins: Gn and Gc (M segment), and a nucleocapsid protein N
and non-structural protein NSs (S segment) [8]. SFTSV is
transmitted by Haemaphysalis longicornis which is a major host [9,
10], and by the Rhipicephalus microplus tick and others [11]. This
virus can be spread through direct contact with blood and body fluids
[12, 13]. SFTSV has been mostly reported in China, South Korea, and
Japan [14-16], but there are some virus infection cases reported in
Vietnam [17]. Of over 7,419 cases of SFTS reported before 2016,
around 355 death cases were estimated in China, and the viruses
were mainly located in Eastern and Central China [18]. The first
SFTS case reported in Japan was in Yamaguchi in 2012. Until the
end of 2013, the total positive number of SFTSV cases had increased
to 40 in Japan with designating emerging diseases [19]. The first
suspected patient of SFTSV was reported on Jeju Island in South
Korea in May 2013, followed by SFTSV isolation by Seoul National
University Hospital [20, 21]. 90% of SFTSV patients were older than
35 years old and most of them were farmers in these countries [22].
In other Asian countries, SFTS cases have been reported in Vietnam
[17], or North Korea [8, 23]. The major clinical symptoms of SFTS
are fever, fatigue, vomiting, diarrhea, thrombocytopenia, and
leukocytopenia as well as multi-system organ failure [24, 25]. The
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cases of infection of these viruses have rapidly increased from 2012
to 2018 [8]. Even though the disease mortality rate of SFTS is
approximately 5-27%, there is no licensed vaccine or therapy
currently.
There recently are a few of vaccine studies of SFTSV with
immunocompromised animal models. Full length of glycoprotein (Gn
and Gc), Nucleocapsid protein (Np), Nonstructural protein (NS), and
RdRp gene cloned DNA vector which can also express target proteins
triggered not only robust IFN-γ against five antigens mentioned
above, but also humoral immune response in BALB/c mice. In
addition, this vector vaccination confers complete protection against
lethal SFTSV infection in old ferret (>4 years) decreasing viral load
in serum [26]. Recombinant VSV having SFTSV glycoproteins
vaccination elicited strong broad-spectrum neutralizing antibodies and
complete protection against lethal various SFTSV strain challenge in
IFNAR K/O C57BL/6 mice [27]. Glycoproteins (Gn&Gc) of SFTSV
are dealt with an important target of vaccination [3, 26, 27]. Injection
of selected SFTSV mAb (monoclonal antibody) from convalescent
patients against glycoprotein N showed complete protection of
IFNAR1 K/O A129 mice with lethal SFTSV challenge [3]. Live
attenuated SFTSV having mutation of NS region also provides
complete cross-genotype protection to lethal challenge. It could induce
a humoral response and reduce viral load in both serum and tissues
[56]. However, immunization with SFTSV NSs protein using Freund’s
adjuvant could not promote virus clearance in C57BL/6J mouse
serum, liver, spleen, and kidney, even though it promoted high titer of
anti-NS antibodies and IFN-γ level [28].
There are lots of vaccine types in these days. Attenuated and
inactivated vaccines have abilities of long-term protection, good
- 10 -
immunogenicity [29]. However, inducing disease and recovery
virulence of pathogens are the main disadvantages [30]. Returning to
natural virulence is a rising problem of this types of vaccine,
resulting in the development of subunit, recombinant, and conjugated
vaccines. Researchers had used subunits of pathogens, conjugated,
and recombinant vaccines [31]. Subunit vaccines includes one or more
proteins, protein-peptide or polysaccharide that are natural pathogenic
structure [32]. Because of low production costs or increasing
bio-safety, scientists have easily used for vaccine study. DNA
vaccine is a format of the administration of a plasmid encoding the
target antigen of a pathogen. DNA directly injected into a cell can be
expressed with the aid of promoter and causes induction of the
immune system. The expressed proteins could be the natural form
that can trigger innate and adaptive immune response. The
advantages of DNA vaccines are producing natural form of antigens,
no possibility of recovery virulence of pathogens, and making
sustainable immunity [33].
Alum adjuvant which is commonly used in human vaccination may
cause a robust Th2 response, but provoke relatively weak
Th1-cell-mediated immunity [34]. Alum with antigens stays in the
injection site by forming depot and slowly releases antigen to the
body, then induces activation of APCs [35]. Recently, it is
controversial that NLRP3-inflammasome would be associated with the
immune-stimulatory characteristic of aluminum adjuvant [36].
FMS-like tyrosine kinase 3 ligand (Flt-3L) is an endogenous small
molecule as a cytokine and growth factor that elevates the number of
lymphocytes by activating the hematopoietic progenitors. The
development of DC and their activation state is also dependent on
Flt-3L cytokine [37]. This cytokine can significantly change the
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absolute number of DC and the subset composition of lymphoid tissue
and blood-borne DC [38, 39]. IL-12 is also cytokine used for adjuvant
of DNA vaccine [40]. IL-12 stimulates protective immune response by
interacting with other cytokines and lymphoid cells. Role of IL-12 has
been known to elevate proliferation of T cells and NK cells, activities
of CD8+ T cells, NK cells, macrophages, and Th1 cells, and induce
production of IFN-γ and other cytokines [41, 42].
Disadvantage of DNA and recombinant subunit vaccines is lower
immunogenic effect [31-33]. To overcome this drawback, recently,
heterologous DNA prime-protein boost immunization process has been
tired in preclinical and even clinical cases. Recombinant subunit
vaccines can trigger a strong antibody immune response and DNA
vaccines are able to elicit the T cell immune response [43]. With
these advantages, heterologous prime-boost immunization could induce
a strong adaptive immunity against antigens [44].
In this study, plasmid encoding ectodomain of SFTSV Gn, Gc, and 
Np-Ns fusion fused with Flt3L at N-terminus and murine IL-12 
cytokine and recombinant SFTSV subunit were evaluated as an 
SFTSV vaccine candidate. Antibody and T cell immunity were 
analyzed in SFTSV DNA plasmid and subunit vaccinated IFNAR 
K/O mice. Then, survival and body weight changes were assessed 
in the DNA and subunit vaccinated IFNAR K/O mice after 
challenging a lethal dose of SFTSV. pSFTSV-IL12 provides 
complete protection against a lethal challenge with high Np and 
Gn specific IFN-γ secreting CD4+ and CD8+ T cells although 
weak antibody dependent immunity was observed. Immunization of 
recombinant Np or Gn enhanced the percentage of antigen 
specific IFN-γ secreting CD4+ and CD8+ T cell and elicited high 
level of antigen specific antibody titer, while they conferred 
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approximately 50% protection against viruses. Vaccination of 
recombinant Gc provided a strong neutralizing effect against 
SFTSV with a high level of antigen specific antibody titer though 
all mice immunized with the Gc subunit were dead. Lastly, 
vaccination of recombinant Gc+Np mixed subunits increased the 
frequency of Np specific IFN-γ and TNF-α producing CD4+ and 
CD8+ T cell and antibody dependent immunity. Besides, 
approximately 90% of the GcP immunized mice survived a lethal 
dose of SFTSV. Therefore, these results suggested that 
pSFTSV-IL12 DNA prime recombinant SFTSV Gc+Np subunits 
boost vaccine could be a novel vaccine for SFTSV by providing a 





All animal experiments were conducted in an Animal Biosafety
Level 3 facility at Seoul National University Hospital. These studies
were approved by Seoul National University Hospital (SNUH IACUC
No.15-0095-C1A0 and IVI IACUC No. 2018-018) and followed by
strict regulation with recommendations in the Guideline of care and
use of laboratory animals.
Preparation of SFTSV DNA plasmids.
To generate plasmids for DNA vaccination, genes including
ectodomains of Gn, Gc (from Genebank accession no. AJO16082.1),
and NP-NS fusion protein (from Genebank accession no. AJO16088.1
and AKI34298.1, respectively) were manufactured (GeneScript,
Piscataway, NJ, USA) and cloned into pGX27 vector (Genexine,
Seongnam, Republic of Korea). All of the genes were fused with the
signal sequence of tissue Plasminogen Activator (tPA, Uniport no.
P00750) and Flt3L (Uniport no. P49771) at N-terminus [1] (pSFTSV,
Part Ⅰ, Fig 1). Furthermore, murine IL-12α and β genes (Uniport no.
P43432) were also manufactured (GenScript) and inserted into
pSFTSV-IL12 (Part Ⅰ, Fig 1).
For expression of SFTSV recombinant subunits, the SFTSV
Nucleocapsid protein gene (from Genebank accession no. KP663733)
was cloned into pET28a+ bacterial expression vector (Novagen,
Gibbstown, NJ, USA). SFTSV Glycoprotein N or C genes (from
Genebank accession no. KF358692) were cloned to pcDNA3
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mammalian expression vector (Thermo Fisher Scientific, Waltham,
MA, USA). These glycoprotein genes have signal peptide on
N-terminal and every gene was fused with a six-histidine tag on
C-terminal. The glycoprotein N or C genes (from Genebank accession
no. KF358692) having signal peptide on N-terminal and Fc fusion
protein on C-terminal were also entered into pCEP4 vector (Thermo
Fisher Scientific, Waltham, MA, USA). This vector was thankfully
provided by Prof. Chung laboratory (Department of Biochemistry and
Molecular Biology, Seoul National University College of Medicine).
Gene expression of plasmid DNAs
To assess the expression of cloned genes in pSFTSV,
pSFTSV-IL12, pET28a+ encoding SFTSV nucleocapsid protein gene
fused with six histidines at C-terminus, pCEP4 including SFTSV
glycoprotein N&C gene with human IgG Fc domain at C-terminus,
and pcDNA3 encoding SFTSV glycoprotein N&C fused with six
histidines at C-terminus, HEK293T cells (ATCC CRL-1573,
Manassas, VA, USA) and BL21(DE3) E.coli were used. HEK293T
cells were transfected with pGX27, pSFTSV, pSFTSV-IL12, pCEP4
including SFTSV glycoproteins, or pcDNA3 inserting SFTSV
glycoproteins plasmids using the polyethylenimine (PEI) transfection
method [2]. Briefly, plasmids and PEI mixture was diluted with
Opti-MEM media (Gibco, Gaithersburg, MD, USA) and incubated
with HEK293T cells for 4hrs. Following incubation, the media was
changed with Dulbecco’s Modified Eagle medium (DMEM) (Gibco)
containing 10% fetal bovine serum (FBS) and incubated in humidified
CO2 atmosphere at 37℃ for 48hrs. Cells and supernatant were
harvested for confirming expression. Cells were lysed with NP-40
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lysis buffer (1% NP-40 in 50mM Tris-HCl, 150mM NaCl, pH8.0)
containing protease inhibitor cocktail (Sigma-Aldrich, St.Louis, MO,
USA). BL21(DE3) E.coli were transformed with pET28a+ vector
having SFTSV NP-His through heat shock at 56℃. Transformed
E.coli were incubated in LB broth (MP biomedical, Irvine, CA, USA)
overnight at 37℃ in bacterial incubator. Incubated E.coli were lysed
with Lysozyme (Thermo Fisher Scientific, Waltham, MA, USA),
protease inhibitor cocktail (Sigma-Aldrich, St.Louis, MO, USA) in the
buffer (20mM sodium phosphate, 0.15M NaCl, pH 7.2) and then
sonicated using Mixonix Sonicator XL2020 (Spectralab, St. Markham,
ON, CA).
For quantification of Flt3L and murine IL-12 cytokines in the
supernatant of transfected HEK293T cells, human Flt3L and mouse
IL-12p70 Quantikine ELISA kits (R&D Systems, Minneapolis, MN,
USA) were used following with manufacturer’s instructions.
Expression of all proteins in culture supernatant and cell lysates was
confirmed by western blot using rabbit anti-Gn, Gc (NBP2-41153 and
NBP2-41156, NOVUS Biologicals, Centennial, Colorado, USA), NP
(produced by custom polyclonal antibody production service through
Abclon, Seoul, Republic of Korea), Histidine (Santa Cruz, California,
USA), and human IgG (Promega, Madison, WI, USA) antibodies,
respectively.
Production of recombinant proteins
SFTSV nucleocapsid proteins cloned into pET28a+ vector were
purified from BL21(DE3) E.coli strain having cloned plasmids. After
induction using 0.1mM isopropyl β-D-thiogalactoside (IPTG) for
18hrs at 16℃, all of the bacterial cells were lysed. The proteins were
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purified using HisTrap HP histidine-tagged protein columns (GE
Healthcare, Chicago, IL, USA) following the manufacturer’s
instruction. And pcDNA3 vector encoding SFTSV glycoprotein N and
C fused with His tag was transfected into HEK293F cells (Thermo
Fisher Scientific, Waltham, MA, USA) using polyethylenimine (PEI)
[2]. Following harvesting supernatant, these proteins were also
purified through HisTrap HP histidine-tagged protein column with the
manufacturer’s instruction. Besides, pCEP4 vector encoded ectodomain
of Gn/Gc fused to the human immunoglobulin Fc region was also
transfected into HEK293F cells with polyethylenimine (PEI) together.
For the over-expression, transfected cells were cultured in the
FreeStyle 293 expression medium (Gibco, Waltham, MA, USA).
MabSelect (GE Healthcare, Chicago, IL, USA) in AKTA start affinity
chromatography (GE Healthcare, Chicago, IL, USA) [3].
Enzyme-linked immunosorbent assays (ELISA)
To determine the titer of antibodies against SFTSV subunits after
3rd immunization, immunoassay 96-well plates (Nunc, Rochester, NY,
USA) were used. 100ng of Proteins were plated on each of wells in
96-well plate for 4℃ overnight. Following this process, all of the well
plates containing proteins were washed with PBST (PBS including
0.05% Tween 20). Every washed well was blocked using five
percentage of skim milk and treated immunized mice sera. Four-folds
dilution with 10point starting 1:100 was conducted every mouse
serum. Sequentially, Horseradish peroxidase (HRP) conjugated goat
anti-mouse IgG antibodies (Thermo Fisher Scientific, Waltham, MA,
USA) were incubated for 1hr at room temperature. Wells were
washed with 0.05% PBST again and incubated with
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3,3’,5,5’-Tetramethylbenzidine (TMB) substrate (KPL, Gaithersburg,
MD, USA) for 7min at room temperature and the reaction was
stopped with 1M phosphoric acid. Microplate reader (Beckman Coulter
Inc, Fullerton, CA, USA) detected plates by using 450nm absorbance.
Viruses and cells
SFTSV (Genbank accession no. MN329148-MN329150) isolated from
Korean SFTS patient. For virus preparation, Vero E6 cells (ATCC
no. CRL-1586) culturing under 10 passages were plated into T-75
flask (Thermo Fisher Scientific, Waltham, MA, USA) with the
confluent monolayer. Viruses were incubated in complete media
(DMEM supplemented with 10% FBS, 1% penicillin-streptomycin
solution) on Vero(E6) cells plated flask for 5days. After 5 days, the
supernatant was harvested and stocked at -80℃. Virus infectivity
was confirmed by plaque assay method with 10 points, ten-folds
dilution. Viruses supernatant was incubated in complete DMEM media
for 1.5hrs at 37℃. Overlay media (DMEM supplemented with 2%
FBS and 1% methylcellulose) was plated on confluent Vero(E6) cells
after incubating viruses for 5 days. Cells were fixed with 100%
methanol (Merck, Darmstadt, Germany) and 4% paraformaldehyde
(Intron, Seongnam, Republic of Korea) for 20min at room temperature.
Permeabilization step using 0.2% Triton X-100 (Sigma, St. Louis,
MO, USA) proceeded for 15min at room temperature. Viral plaques
were detected by rabbit anti-SFTSV NP antibodies (Abclon) and
HRP conjugated goat anti-rabbit IgG antibodies (Invitrogen, Waltham,
MA, USA) using 3,3’-Diaminobenzidine (DAB) substrate (Merck,
Darmstadt, Germany).
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Focus Reduction Neutralization Test (FRNT)
Mice sera immunized with SFTSV subunits were incubated with
100FFU SFTSV at four dilution points starting from 1:100 for an
hour at 4℃. Mixture of SFTSV and serum was placed into confluent
Vero(E6) cells monolayer in each well of 24 well cell culture plate
(SPL Life Sciences, Pocheon, Republic of Korea) for 1.5hrs at 37℃.
Viruses were incubated in overlay media (DMEM supplemented with
2% FBS and 1% methylcellulose) for 7 days at 37℃ in a CO2
incubator. Cells were fixed with 100% methanol (Merck, Darmstadt,
Germany) and 4% paraformaldehyde (Intron, Seongnam, Republic of
Korea) for 20min at room temperature. Permeabilization step using
0.2% Triton X-100 (Sigma, St. Louis, MO, USA) proceeded for 15min
at room temperature. Viral plaques were detected by rabbit
anti-SFTSV NP antibodies (Abclon) and HRP conjugated goat
anti-rabbit IgG antibodies (Invitrogen, Waltham, MA, USA) using
3,3’-Diaminobenzidine (DAB) substrate (Merck, Darmstadt, Germany).
Quantitative reverse transcript-polymerase chain
reaction (qRT-PCR)
Total RNA was extracted from the plasma of SFTSV-infected mice
after immunizing using Trizol LS reagent (Life Technologies,
Carlsbad, CA, USA) according to the manufacturer’s instruction.
Extracted RNA was reverse transcribed to cDNA using the
HiSenScript RH (-) RT Premix kit (Intron, Seongnam, Republic of
Korea). cDNA was quantified using TaqMan Universal Master Mix 2
(Applied Biosystems, Waltham, MA, USA). Viral copy numbers were
determined by BioRad CFX to connect real-time system (Bio-Rad,
Hercules, CA, USA) under following conditions: uracil-N-glycosylase
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incubation at 50˚C for 2 min, polymerase activation at 95˚C for 10
min, denaturation at 95˚C for 15 s, annealing and extension at 53˚C
for 1 min for 45 cycles. Primer set and detecting probe was derived
from the NP gene of SFTSV: NP forward
(5’-CCTTCAGGTCATGACAGCTGG-3’), NP reverse
(5’-ACCAGGCTCTCAATCACTCCTGT-3’) and detecting probe
(5’-6FAM AGCACATGTCCAAGTGGGAAGGCTCTG-BHQ1-3’).
Flow cytometry
Mice spleens were ground by 70um cell strainer (BD Biosciences,
San Jose, CA, USA) into RPMI 1640 media (Gibco, Waltham, MA,
USA). RBC lysing buffer Hybrid-MaxTM (Sigma, St. Louis, MO,
USA) was treated into spleen grinding supernatant. Splenocytes were
cultured with 3 μg of purified NP, Gn, Gc proteins for 18hrs at 37℃
CO2 incubator in complete RPMI (supplemented with 10% FBS, 1%
penicillin& streptomycin solution) on 96-well cell culture plate. To
detect intracellular cytokine IFN-γ and TNF-α, Golgi-plug (BD
Bioscience) was treated for 5hrs at 37℃ CO2 incubator and then
blocked by using ultra-block solution (10% rat sera, 10% hamster
sera, 10% mouse sera) (Sigma). Following blocking, anti-CD3
(145-2c11) (BD Bioscience), CD4 (RM4-59) (BD Bioscience), and CD8
(53-6.7) (Biolegend, San Diego, CA, USA) conjugated fluorescent dyes
antibodies were treated for 30min, at room temperature. All of
splenocytes bound with surface marker were fixed and permeabilized
with Cytofix/Cytoperm kit (BD Bioscience). Then, anti-IFN-γ 
(XMG1.2) antibody (BD pharmingen, Franklin Lakes, NJ, USA) and
TNF-α (MF6-XT22, Affymetrix, Cleveland, OH, USA) detected
intracellular cytokines. Stained cells were detected through the
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CytoFLEX S flow cytometer (Beckman Coulter Inc, Brea, CA, USA).
Data were analyzed by FLowjo software (Tree Star, Ashland, OR,
USA).
Immunization of mice and SFTSV challenge
8-to 12-week-old female C57BL/6 WT mice (Koatech, Pyeongtaek,
Republic of Korea) or C57BL/6 Interferon α/β receptor K/O mice
were used for immunization and challenge. They were maintained in
the pathogen-free animal facility at Seoul National University College
of Medicine. 4 μg of Mock vector (pGX27), pSFTSV, and
pSFTSV-IL12 DNAs were intramuscularly immunized to mice by
electroporation using Orbijector EP-I model (SL Vaxigen Inc.,
Seongnam, Republic Korea) in leg three times at two-week intervals.
10 μg of SFTSV NP-His, Gn-Fc, Gc-Fc, Fc subunits with aluminum
hydroxy chloride (Alhydrogel® adjuvant 2%, InvivoGen, Hong Kong)
were immunized through subcutaneous injection three times at
two-week interval during 6weeks. Mice sera were collected at a
week after 3rd immunization. A thousand FFU of SFTSV were
challenged two weeks later after the final immunization. Survival rate
and body weight change were recorded until 14 day post-infection
(dpi).
Hematology
To analyze hematological data, lots of blood was prepared through
cardiac puncture in euthanized animals. The blood was collected into
0.5M EDTA(Enzynomics, Daejeon, Republic of Korea) coated tubes.
Before the assessment of platelet counts, 4% paraformaldehyde was
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added to EDTA-anti-coagulated whole blood samples at a 1:1 ratio
for inactivating the virus. The platelet counts were analyzed using
ADVIA 2012i Hematology System (Siemens Healthimeers, Erlangen,
Germany).
Data analysis
Data was analysed by the Graph Pad Prism 8.0 software
(GraphPad Software, La Jolla, CA, USA). Statistical analysis was
performed using a two-tailed Student’s t-test with a 95% confidence
interval or one-way analysis of variance (ANOVA) followed by
Newman-Keuls t-test for comparisons of values among different
groups. Data are expressed as the mean ± standard deviation (S.D.).
Data analysis on survival rates was performed using the Mantel-Cox




Evaluation of single plasmid DNA vaccine
encoding IL-12 and SFTSV antigens.
Characterization of SFTSV DNA vaccines and
their gene expression.
  Four major antigens (Nucleocapsid protein (Np), Nonstructural 
protein (NS), and Glycoprotein (N&C)) of SFTSV were inserted 
into the pGX27 vector plasmid (Part Ⅰ, Fig 1). Full lengths of the 
NP-NS fusion protein gene linked through peptide 
(GSGSGSGSGSGRA) were under the control of the RSV promoter 
which provides high levels of expression in many cell types [45, 
46]. Extracellular domains of the SFTSV Gn and Gc genes were 
separately cloned into the vector and under control of the CMV 
promoter and IRES sequence. All expressed antigens were fused 
with the extracellular domain of Flt3L and signal sequence of 
tissue plasminogen activator (tPA) in N-terminus to promote 
antigen presentation and trafficking of the fusion proteins as 
previously described [47]. Murine IL-21α and β gene which are 
growth factors for activated T and NK cells were cloned into the 
vector to stimulate the production of IFN-γ from antigen-specific 
T cells [48]. Secretion cytokines and SFTSV antigens from 
HEK293 cells transfected with indicated DNAs were analyzed by 
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ELISA and Western blot (Part Ⅰ, Fig 2). All SFTSV antigens 
were confirmed at whole cell lysate (left panel) and supernatant 
(right panel) of transfected cells (Part Ⅰ, Fig 2B).
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Figure 1. Map of plasmid encoding SFTSV antigen and IL-12.
SFTSV surface protein Gn and Gc, and Np-NS fusion protein were
inserted into the pGX27 vector (pSFTSV). pSFTSV-IL-12 vector
includes murine IL-12α and β gene to enhance cellular immunity.
ColE1, ColE1-type bacterial origin of replication; gIVS, rabbit β
-globin intervening sequence; KanR, kanamycin resistance gene;
IRES, internal ribosome entry site.
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Figure 2. Expression of each of SFTSV antigens and cytokines after
SFTSV DNA transfection.
(A) Expression of Flt3L and IL-12 cytokines in supernatant of
HEK293 cells transfected with each of DNA was assessed by ELISA
measurement. Data are presented as mean + S.D from triplicated
experiments. (B) Expression of viral antigens, Np-NS fusion (
~80kDa), Gn(~74kDa), and Gc(~71kDa) proteins, in whole-cell lysates
(left panels) and culture supernatants (right panel) from transfected
HEK293 cells, was confirmed by western blot analysis using anti-Gn,
Gc, or NP antibodies. The position of each of the viral proteins is
indicated by an arrow. β-actin was used as loading control.
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Antibody and T cell responses against the viral
antigens by immunization of the DNA vaccines.
  Next, antibody and T cell immune responses in IFNAR K/O mice 
vaccinated mock, pSFTSV, and pSFTSV-IL12 DNA plasmids were 
evaluated. Antibody response against the Np antigen had 
considerably increased (mean titer ± S.D.: 255 ± 63, n=3) only in 
the mice vaccinated with pSFTSV-IL12 one week after the third 
immunization (Part Ⅰ, Fig 3A). SFTSV Gn and Gc specific 
antibodies were hardly detectable in all the DNA vaccine groups, 
indicating that these DNA vaccines may not efficiently induce 
SFTSV glycoproteins specific antibodies, but SFTSV NP-specific 
antibodies could be induced in the vaccination of pSFTSV-IL12. 
Neutralizing assay tests using sera from mice vaccinated with 
mock, pSFTSV, and pSFTSV-IL12 DNA one week after the third 
immunization showed neutralizing titer of pSFTSV-IL12 vaccine 
group, which was higher than both the mock and pSFTSV vaccine 
groups (Part Ⅰ, Fig 3B). 
  To assess T cell immunity in IFNAR K/O mice vaccinated with 
mock, pSFTSV, and pSFTSV-IL12 DNA, a percentage of SFTSV 
antigens specific IFN- γ producing T cells in the spleen of mice 
immunized with SFTSV DNA vaccines was measured (Part Ⅰ, Fig 
3C and D). Splenocytes from vaccinated mice were stimulated 
with SFTSV NP or Gn antigens and IFN-γ secreting T cell 
subsets were analyzed by flow cytometry. The percentage of NP 
or Gn specific IFN-γ secreting CD4+ and CD8+ T cells of mice 
vaccinated with pSFTSV-IL12 was considerably higher than those 
of mice vaccinated with the mock vector. Even though the levels 
were not statistically significant, the antigen specific IFN-γ 
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producing T cell from pSFTSV vaccinated mice were commonly 
elevated. All of this data indicated that the expression of IL-12 
may increase T cell immunity against the viral antigens. 
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Figure 3. Antibody or T cell immune response of SFTSV DNA
vaccine against viruses.
(A) Anti-Np IgG response was measured by ELISA at two weeks
after the third immunization of each of DNA are presented. Cut-off
titers (dashed line, mean O.D. + 3x S.D. at 1:100 diluents) was
determined by sera of vector immunized mice. Error bar: mean ± S.D.
(B) Neutralizing antibody response to SFTSV of each indicated DNA
vaccines. The amount of neutralizing antibody was determined based
on FRNT50. *, p < 0.05.
(C and D) Antigen specific IFN-γ cytokine-producing CD4+ and CD8+
T cells from immunized mice at two weeks after the third
vaccination were analyzed using flow cytometry after stimulation with
the indicated antigens. Representative flow cytometric results are
displayed (C) and the percentage of IFN-γ secreting CD4+ or CD8+ T
cells were summarized (D). Data are shown as mean + S.D. from
duplicate assays with three mice per group. *, p < 0.05; **, p < 0.01.
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Protection of DNA plasmid vaccine encoding
SFTSV antigens and IL-12 anainst .
  To assess whether the SFTSV DNA vaccines can provide a 
protective ability against lethal virus challenge, mock vector, 
pSFTSV, or pSFTSV-IL12 plasmid DNA were immunized to IFNAR 
K/O mice three times through electroporation before injection of 
105 FFU SFTSV (Part Ⅰ, Fig 4). After virus infection, all groups 
of mice were monitored for survival rate, body weight, platelet 
counts, and viral titers in plasma. Following the challenge virus, 
all of the mice (n=5) immunized with mock vector were dead on 5 
day post-infection, while 40% (2 of 5) of the pSFTSV vector 
immunized mice survived, and all mice vaccinated with 
pSFTSV-IL12 were completely protected from the viruses (Part 
Ⅰ, Fig 4A, left panel). Consistently, the mean body weight of 
mock-vaccinated mice rapidly decreased to around 70% of their 
original body weight on 4 day post-infection, and then all the mice 
were dead. However, the pSFTSV-IL12 vaccine group lost weight 
until they reached 82% of their original body weight on day 4 
after challenge and recovered thereafter. Surviving mice in the 
pSFTSV vaccine group lost weight until they reached 78% of their 
original body weight on 6 day post-infection and then recovered. 
(Part Ⅰ, Fig 4A, right panel). When I examined the platelet 
counts of each immunization group during the acute phase of 
infection, the mock vector injection group dramatically decreased 
until dead, while the counts of mice vaccinated with pSFTSV or 
pSFTSV-IL12 slightly declined and the pSFTSV-IL12 group’s 
counts recovered at 4 day post-infection (Part Ⅰ, Fig 4B, left 
panel). Furthermore, viral titers were significantly reduced in the 
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plasma of the pSFTSV or pSFTSV-IL12 vaccinated mice 
compared to the mock vector vaccinated mice at 4 day
post-infection (Part Ⅰ, Fig 4B, right panel). In detail, despite 
similar initial viral titers (~ 106 copies/ml of plasma) at 2 day
post-infection in all vaccinated groups, the titer of pSFTSV-IL12 
vaccinated mice (mean ± S.D. = 4.2 × 106 ± 4.6 × 106) was 
about five to fifty times lower than that of pSFTSV immunized 
mice (mean ± S.D. = 2.1 × 107 ± 1.7 × 107) or mock immunized 
mice (mean ± S.D. = 2.0 × 108 ± 1.9 × 108) at day 4
post-infection, respectively. 
- 31 -
Figure 4. Survival, relative body weight change, hematological
analysis, and distribution of viral RNA copy number in plasma of
SFTSV DNA plasmid immunized IFNAR K/O mice against lethal
SFTSV challenge.
(A) Survival proportion (left panel) and body weight change (right
panel) of three times vaccination of indicated DNAs into IFNAR K/O
mice (n=5/group) and challenged with 105 FFU of SFTSV through
S.C. at two weeks after vaccination. (B) Platelet counts (left panel)
and viral loads in plasma (right panel) of vaccinated mice on 2 day
post-infection (D2) and 4 dpi (D4). Uninf, uninfected; n=3~4
mice/group. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
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Part Ⅱ.
Evaluation of SFTSV subunit vaccine.
Characterization and expression of recombinant
SFTSV subunits.
  Three major SFTSV antigens (Nucleocapsid protein and 
Glycoprotein N&C) were cloned into different vectors to be 
purified with a high rate of purity. Recombinant SFTSV 
Nucleocapsid proteins (NP) were fused with six histidine peptides 
at both N and C-terminus in the pET28a+ bacterial vector (Part 
Ⅱ, Fig. 1A). T7 promoter and lac I genes in the pET28a+ vector 
suppress the target protein gene without lactose or IPTG [49]. 
The expression of recombinant SFTSV NP in BL21(DE3) E.coli 
whole cell lysate was detected using the anti-His HRP antibody 
(Part Ⅱ, Fig. 1E). Glycoprotein N&C, which are viral surface 
proteins, were conjugated with signal peptides at N-terminus and 
human IgG Fc fragment at C-terminus and cloned into the pCEP4 
vector to create a specialized protein purification from mammalian 
cells (Part Ⅱ, Fig.1C). The plasmid vector is under the control of 
the CMV promoter and enhanced gene expression efficiency and 
maintenance by the EBNA-1 gene. The recombinant Gn or Gc 
proteins could be secreted thanks to signal peptides to the 
extracellular area. Recombinant Gn or Gc-Fc proteins that could 
be expressed outside of HEK293F cells reacted with the 
anti-human IgG HRP antibody (Part Ⅱ, Fig 1G). Only human IgG 
Fc proteins were also cloned into the pCEP4 vector plasmid to be 
used as a negative control (Part Ⅱ, Fig 1B). Fc proteins were 
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also confirmed to be expressd outside of HEK293F cells (Part Ⅱ, 
Fig. 1F). Glycoproteins fused with signal peptides at N-terminus 
and six histidine at C-terminus were inserted into the pcDNA3 
vector (Part II, Fig 1D). This plasmid vector also has the CMV 
promoter which can strongly express the genes. The recombinant 
Gn and Gc proteins expressed in HEK293F cells were confirmed 




Figure 1. Map of SFTSV subunits expression vector and recombinant
proteins expression test.
(A-D). Each of protein expression plasmid and schematic diagram
showing recombinant SFTSV proteins size and composition.
(A) Recombinant SFTSV N protein fused with six histidine gene was
inserted into pET28a+ vector. Ori; KanR, Kanamycin resistance gene;
Iac I, regulatory gene for Iac operon.
(B and C) Human IgG Fc fragment or recombinant SFTSV fused
with Fc fragment gene was inserted into pCEP4 vector plasmid. Ori,
pUC origin; ApmR, Ampicillin resistance gene; HygR; Hygromycin
resistance gene; CMV promoter; SV40 PA, SV40 poly A; EBNA-1,
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EBV origin of nuclear antigen.
(D) Recombinant SFTSV Glycoprotein N&C (Gn&Gc) with six
histidine peptides gene was inserted into pcDNA3 vector. Ori; SV40
PA, SV40 poly A; NeoR, Neomycin resistance gene; KanR,
Kanamycin resistance gene; CMV promoter.
(E-H) Confirmation of recombinant SFTSV nucleocapsid protein (Np)
(E), Fc protein (F), Glycoprotein N&C(Gn&Gc) fused with Fc
fragment (G) or His peptides (H) expression by immunoblot analysis
using anti-His-HRP or anti-human IgG-HRP antibodies.
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Production of recombinant SFTSV nucleocapsid
protein-tagged His peptides from E.coli
  Isopropyl-β-thiogalactopyranoside(IPTG) has been used for the 
overexpression of recombinant proteins in BL21(DE3) E.coli 
system. I used this overexpression system to purify recombinant 
SFTSV Nucleocapsid proteins (rSFTSV NP). To determine the 
high-level expression condition, I tested several induction 
processes based on two different temperatures (16℃ and 37℃) 
and four various IPTG concentrations (0.0, 0.1, 0.5, and 1.0mM). I 
also checked whole bacterial cell lysate, supernatant after 
centrifuge of lysate, and pellets after centrifuge of lysate to 
confirm whether recombinant NPs were soluble or insoluble 
proteins. Bacterial cells were induced with each of the different 
IPTG concentrations at an optical density (OD) at 600nm of 
0.6-0.8, and they were cultured overnight at 16℃ or for 5hrs at 
37℃. Overall SDS-PAGE results showed 16℃ induction could 
produce more recombinant NPs in all of the whole cell lysate, 
supernatant, and pellets (Part Ⅱ, Fig 2A). Although N proteins 
were placed in both supernatant and pellets, these proteins were 
usually found in the supernatant, suggesting that recombinant 
SFTSV NP may be soluble proteins. Also, NP could be induced 
with a high level at over 0.1mM IPTG condition. Immunoblot 
analysis of recombinant NPs of 16℃ and 37℃ with 0.1mM IPTG 
induction showed that 0.1mM IPTG induction at 16℃ would be the 
best process of SFTSV NP overexpression (Part Ⅱ, Fig 2B).
  Next, I aimed to develop a step to further purify the high purity 
of recombinant SFTSV N proteins. Because lots of other 
non-target proteins in bacterial cell lysate could bind to Ni-NTA 
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bead, I had to remove non-target proteins for the high purity 
SFTSV NP using a certain concentration of imidazole. The 
washing step was processed with various concentrations of 
imidazole (0-200mM) and recombinant SFTSV NPs were eluted by 
250mM imidazole, then SDS-PAGE analysis showed the purity of 
recombinant target proteins (Part Ⅱ, Fig 3A-E). 10mL of 
BL21(DE3) E.coli transformed rSFTSV NP plasmid vector was 
induced in 16℃ overnight with 0.1mM of IPTG, then the E.coli 
lysate was incubated with Ni-NTA bead. First, I washed rSFTSV 
NP binding to Ni-NTA bead with an increasing imidazole 
concentration from 0mM to 200mM. After treating with 100mM of 
imidazole, other non-target proteins were cleared (Part Ⅱ, Fig 
3A). Next, I tested washing two times with a lower concentration 
(10mM) imidazole (Part Ⅱ, Fig 3B) and washing two times with a 
higher concentration (70 and 100mM) imidazole (Part Ⅱ, Fig 3C). 
Higher concentration washing was more efficient to remove 
non-specific proteins. Then, washing two times with 70mM 
imidazole and three times with 100mM imidazole showed gradual 
removal of non-specific proteins (Part Ⅱ, Fig 3D). Finally, the 
process of washing five times with 1mL of 100mM imidazole and 
1mL of 250mM imidazole for elution provided a high purity of 
rSFTSV NP, furthermore, target proteins were no longer bound to 
bead after elution (Part Ⅱ, Fig 3E). These recombinant N proteins 
were confirmed by immunoblot using anti-histidine or anti-NP 
antibodies (Part Ⅱ, Fig 4). 
  To sum up, BL21(DE3) E.coli transformed rSFTSV-NP vector 
plasmid could be overexpressed at 16℃ overnight with 0.1mM 
IPTG, then washing 5 times with 100mM imidazole and 2-3mL 
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250mM imidazole elution per 1L E.coli culture was the best 
condition for rSFTSV-NP purification. 
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Figure 2. Recombinant SFTSV nucleocapsid protein expression test
depends on Isopropyl-β-thiogalactopyranoside (IPTG) concentration or
temperature.
(A) SDS-PAGE of whole cell lysate (WCL), supernatant after
centrifuge of cell lysate (Supernatant), and pellet after centrifuge of
cell lysate (Pellet) from BL21 E.coli induced by various IPTG
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concentration (0.0, 0.1, 0.5, and 1.0mM) in 16℃ for 18hrs or 37℃ for
5hrs. (B) Western blot analysis of recombinant N proteins in some
induction conditions. The position of recombinant SFTSV N proteins
is indicated by an arrow. Sup: Supernatant of lysate after centrifuge,
P: Pellet of lysate after centrifuge.
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Figure 3. Washing condition of recombinant SFTSV N protein using
various imidazole concentration.
(A-E). SDS-PAGE of washing conditions of recombinant SFTSV N
proteins using a variety of imidazole concentration. FT, Flow-through
after Ni-NTA bead binding; Washing, washing step of bead binding
rSFTSV Np-His; Elution, elution of rSFTSV Np-His from bead
using 250mM imidazole; B, Ni-NTA bead after eluting of rSFTSV
Np-His. The position of recombinant SFTSV N proteins is indicated
by an arrow.
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Figure 4. High purity of recombinant SFTSV N protein-tagged His
peptides.
SDS-PAGE and Western-blot analysis high purity of recombinant
SFTSV N protein expressed in BL21 E.coli. SDS-PAGE shows
Protein marker (M), protein purified from BL21 E.coli transformed
empty pET28+ vector as a negative control (-), and recombinant
SFTSV N protein expressed from BL21 E.coli and washed with
imidazole (NP). Anti-Histidine-HRP antibody and rabbit polyclonal
anti-N protein-specific antibody detected target recombinant protein in
Western blot.
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Purification strategies of recombinant SFTSV
glycoproteins using mammalian cells.
  Glycoproteins N&C which are membrane proteins of SFTSV are 
important for entering the host cell to infect [50, 51]. For this 
reason, these proteins have been used for vaccine targets [3, 26, 
27]. Recombinant SFTSV glycoprotein N&C (Gn&Gc) fused with 
Fc region a C-terminus cloned vector plasmid was thankfully 
provided by Prof. Chung. HEK293T and HEK293F cells were used 
for expression and purification of glycoproteins, respectively. 
First, I tested whether glycoproteins fused with Fc fragments 
bound to protein A/G bead. The supernatant of HEK293T cells 
transfected was treated with protein A/G bead for an hour at 4℃. 
The supernatant of HEK293F cells without transfection was the 
negative control. Immuno-blot analysis of supernatant or bead 
after centrifuge of bead-bound with glycoproteins was showed 
using anti-human IgG Fc fragment HRP antibody (Part Ⅱ, Fig 5). 
Reactivity of Gn or Gc-Fc proteins with antibodies at Bead lane 
indicated that Gn or Gc-Fc proteins could be expressed in 
mammalian cells and bind with protein A/G bead stably. 
  To obtain a huge amount of rSFTSV Gn or Gc proteins, I tested 
four different transfection conditions with rSFTSV glycoproteins. 
Polyethylenimine (PEI) was used for transfection and the DNA to 
PEI ratio was 1:4. A million cells per mL were transfected with 0, 
1.0, 1.5, and 2.0 μg DNA per ml, respectively, then cells were 
analyzed by immunofluorescence confocal microscopy during 1 
day post-transfection (dpt). The percentage of transfected cells 
showed 1.0 μg per mL DNA was the most efficient condition (Part 
Ⅱ, Fig 6A). Next, I tested translation efficiency after transfection 
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with the rSFTSV glycoproteins plasmids. The supernatant of 
transfected HEK cells was bound to protein A/G bead at each 2-5 
days post-transfection. Each day’s protein amount was analyzed 
based on the BSA amount (Part Ⅱ, Fig 6B, bottom panel). The 
protein amount was the highest at 2 day post-transfection and 
gradually decreased until day 5 (Part Ⅱ, Fig 6B). It is important 
to maintain cell viability for protein expression after transfection. 
  The viability of HEK293F cells was also tested during 7 day 
post-transfection. Transfected HEK cells without media change 
gradually decreased, and finally all cells were dead at 7 day 
post-transfection, while the viability of HEK cells with a media 
change at dpt 2 and 5 increased until dpt 7 (Part Ⅱ, Fig 6C). 
With these conditions, the rSFTSV Gn and Gc-Fc proteins were 
purified using the AKTA system. The supernatant of HEK293F 
cells without transfection did not display any proteins in the first 
lane (-). The flow-through of transfected HEK293F cells 
supernatant after protein A/G bead binding showed other 
non-specific proteins, while any protein was not shown in the 
washing solution lane with buffer A (20mM sodium phosphate, 
0.15M NaCl, PH 7.2) and the elution lane showed a high purity of 
rSFTSV Gn or Gc-Fc proteins (Part Ⅱ, Fig 7A and B). rSFTSV 
glycoproteins were confirmed by immunoblot analysis using 
anti-human IgG Fc region antibodies.
  Collectively, these results indicated that HEK293F cells 
transfected with 1 μg per mL of rSFTSV glycoproteins and 4 μg 
per mL PEI during 6 days post-transfection could express a high 
level of rSFTSV Gn and Gc-Fc, and the proteins were washed 
with buffer A (20mM sodium phosphate, 0.15M NaCl, PH 7.2), 
then eluted with buffer B (0.1M sodium citrate, pH 3.0).
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  To acquire various recombinant SFTSV glycoproteins form, I 
designed rSFTSV glycoproteins fused with six histidine at 
C-terminus. His fused glycoproteins were also tested at a high 
expression condition and washing step. The transfection condition 
of rSFTSV glycoprotein fused Fc were used for purifying SFTSV 
Gn and Gc-His proteins. When I measured the translation 
efficiency of rSFTSV Gn-His protein, the protein amount was the 
highest on 5 day post-transfection based on the BSA amount 
(Part Ⅱ, Fig 8). Furthermore, due to the removal of non-specific 
proteins from the Ni-NTA bead, rSFTSV Gn and Gc-His proteins 
also needed the washing process. Recombinant Gn-His proteins 
were washed with 500ul of 0 to 150mM imidazole concentration 
and eluted with 250mM imidazole. Non-target proteins were 
gradually removed by increasing the imidazole concentration from 
20mM to 150mM. However, over 70mM imidazole could elute 
rSFTSV Gn-His proteins from bead (Part Ⅱ, Fig 9A). For this 
reason, I designed a washing step using 500ul of 50mM imidazole 
five times. Beads were gradually washed from the non-target 
proteins without eluting target Gn-His proteins. Finally, a high 
purity of Gn-His protein was obtained at 250mM imidazole (Part 
Ⅱ, Fig 9B). rSFTSV Gn-His proteins were assessed by western 
blot using an anti-histidine antibody (Part Ⅱ, Fig 9A and B). 
Recombinant Gc-His proteins were tried with a rinse of 500ul of 
50, 40, 30, 25, and 20mM imidazole five or six times. The 40 and 
50mM washing steps were efficient for removing non-specific 
proteins, but, lots of Gc-His proteins were eluted at every stage 
during the 40 and 50mM washing step (Part Ⅱ, Fig 9C and D). A 
lower imidazole concentration of 25 and 30mM washing steps 
showed a small amount of SFTSV Gc-His proteins were detached 
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from the bead in every washing stage (Part Ⅱ, Fig 9E and F). A 
high purity of Gc-His protein without losing was obtained in 
20mM imidazole washing (Part Ⅱ, Fig 9G). A high purity of 
rSFTSV Gn and Gc-His proteins were assessed by SDS-PAGE 
and immuno-blot using anti-histidine antibodies (Part Ⅱ, Fig 10).
  Altogether, data showed that washing with 500ul of 50mM 
imidazole five times may be the best purification process for 
rSFTSV Gn-His proteins and washing with 1mL of 20mM 
imidazole six times could be the best purification method for 
rSFTSV Gc-His proteins. 
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Figure 5. Bead binding ability of recombinant SFTSV glycoprotein
N&C fused with human IgG Fc fragment.
Western-blot analysis of binding ability of recombinant SFTSV
glycoprotein N&C fused human IgG Fc domain to protein A/G bead.
Supernatant of empty pCEP4 vector transfected HEK293T cells (-),
supernatant of Gn-Fc plasmid transfected HEK293T cells (Gn-Fc), or
supernatant of Gc-Fc plasmid transfected HEK293T cells (Gc-Fc)
were bound by protein A/G bead. Sup: Supernatant after centrifuge of
bead, Bead: Bead after centrifuge of bead. Reactivity of supernatant
of recombinant Gn or Gc-Fc after centrifuge post bead binding, and
bead to anti-human IgG HRP antibody.
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Figure 6. Expression condition of SFTSV glycoprotein N&C fused
with human IgG Fc fragment.
(A) Immunofluorescence confocal microscopy using To-pro-5 antibody
(α-nucleus) and anti-IgG Fc antibody (α-human IgG Fc) showed
nucleus and recombinant SFTSV glycoprotein C (Gc) fused with
human IgG Fc fragment in HEK293F cells after transfection,
repectively. Transfection DNA amount was indicated with 0.0, 1.0, 1.5,
and 2.0 μg per ml. Transfection rate(%), 0.0 μg DNA/ml: 0.0%, 1.0 μg
DNA/ml: 42.7%, 1.5 μg/ml: 39.1%, 2.0 μg/ml: 33.3%. Transfection
percentage = transfected cells / total HEK293F cells X 100.
(B) SDS-PAGE of protein A/G bead binding recombinant SFTSV
Gc-Fc proteins 2-5 days post-transfection (dpt). Protein amount
was determined by the BSA amount displayed in lower SDS-PAGE
gel using the Image J program.
(C) Viability of HEK293F cells after transfection with changing media
(Redline) or without changing media (Blackline) during 7 days 
post-transfection (dpt).
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Figure 7. Purification of recombinant glycoprotein N&C fused with
human IgG Fc fragment.
(A and B) SDS-PAGE and Western-blot analysis of high purity
purification of recombinant SFTSV glycoprotein N&C fused with Fc
fragment using AKTA start. Flow through, Flow-through after
protein A/G bead binding; Washing, washing step of bead binding
rSFTSV Gn or Gc-Fc. Recombinant proteins (Gn-Fc and Gc-Fc)
were assessed by immunoblot analysis using the anti-human IgG Fc
antibody.
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Figure 8. Expression condition of SFTSV glycoprotein N&C fused
with His peptides.
SDS-PAGE analysis of translation efficiency of recombinant
glycoprotein N protein in the supernatant of transfected HEK293F
cells. Recombinant Gn-His proteins binding with Ni-NTA bead
during 0-6 day post-transfection (dpt) were assessed. The protein
amount was determined by the BSA amount displayed in lower
SDS-PAGE gel using the Image J program.
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Figure 9. Washing conditions of recombinant SFTSV glycoprotein
N&C fused with His peptides using various imidazole concentration.
(A and B) SDS-PAGE and Immunoblot analysis of recombinant
SFTSV glycoprotein N (Gn) fused His peptides washing condition
using various imidazole concentrations. FT, Flow-through after
Ni-NTA bead binding; Washing, washing step of bead binding
rSFTSV Gn-His; Elution, elution of rSFTSV Gn-His from bead
using 250mM imidazole; B, Ni-NTA bead after eluting of rSFTSV
Gn-His. Position of recombinant SFTSV Gn is indicated by arrow.
The recombinant proteins (Gn-His) were assessed by immunoblot
analysis using the anti-Histidine-HRP antibody.
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Figure 9. A variety of imidazole concentration washing conditions of
recombinant SFTSV glycoprotein N&C fused with His peptides.
(C-G) SDS-PAGE and Immunoblot analysis of recombinant SFTSV
glycoprotein C (Gc) fused His peptides washing condition using
various imidazole concentrations. FT, Flow-through after Ni-NTA
bead binding; Washing, washing step of bead binding rSFTSV
Gc-His; Elution, elution of rSFTSV Gc-His from bead using 250mM
imidazole; B, Ni-NTA bead after eluting of rSFTSV Gc-His.
Position of recombinant SFTSV Gc is indicated by arrow. The
recombinant proteins (Gc-His) were assessed by immunoblot analysis
using the anti-Histidine-HRP antibody. (C-G) The right lower white
letter displayed at each of SDS-PAGE panel showed washing
imidazole concentration of recombinant SFTSV Gc proteins.
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Figure 10. Purification of recombinant glycoprotein N&C fused with
His peptides.
(A and B) SDS-PAGE and Immunoblot analysis of high purity
purification of recombinant SFTSV glycoprotein N&C fused with
Histidine peptides using AKTA start.
Flow through, Flow-through after Ni-NTA bead binding; Washing,
washing step of bead binding rSFTSV Gn or Gc-His. Recombinant
proteins (Gn-His and Gc-His) were assessed by immunoblot analysis
using the anti-Histidine-HRP antibody.
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Protection of single subunit vaccine against a
lethal dose of SFTSV in IFNAR K/O mice.
  Antibody dependent immunity and T cell immune responses in 
IFNAR K/O mice vaccinated with a single SFTSV subunit vaccine 
were evaluated. Vaccination with a single SFTSV subunit with 
alum adjuvant significantly increased antigen specific antibody titer 
for immunized antigens in IFNAR K/O mice (Np: mean ± S.D. = 
102,400 ± 0.0, n=5, Gn: mean ± S.D. = 15,040 ± 5,903, n=5, Gc: 
mean ± S.D. = 56,320 ± 42,065, n=5) (Part Ⅱ, Fig 11B). The 
neutralizing antibody titer of mice immunized with recombinant 
subunit SFTSV Gn-Fc (mean ± S.D. = 135.8 ± 83.15, n=5) and 
recombinant subunit SFTSV Gc-Fc (mean ± S.D. = 639.9 ± 
181.0, n=5) against SFTSV were approximately sixteen times and 
eighty times higher than those of the control (Fc) (mean ± S.D. = 
8.78 ± 7.36, n=5) group. But, the recombinant subunit SFTSV 
Np-His (mean ± S.D. = 23.19 ± 8.09, n=5) immunization group 
barely had neutralizing antibodies against viruses compared to the 
control (PBS) (mean ± S.D. = 24.14 ± 15.88, n=5). (Part Ⅱ, Fig 
11C).
  The T cell-mediated immunity in IFNAR K/O mice immunized 
with the recombinant SFTSV Np, Gn, and Gc subunits were also 
analyzed. Antigen-specific CD4+ and CD8+ T cell responses 
producing IFN- γ, and TNF-α in the spleen of mice were 
evaluated by flow cytometry. Antigen-specific CD4+ and CD8+ T 
cells from immunized mice were stimulated with immunized 
antigens (Np, Gn, or Gc) (Part Ⅱ, Fig 11D). The frequency of 
antigen-specific TNF-α producing CD4+ and CD8+ T cells 
stimulated with immunized soluble antigens for all immunized 
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groups was elevated compared to those of unstimulated T cells. 
The percentage of IFN- γ and TNF-α double-positive cells was 
extremely low for all immunized groups. Interestingly, the level of 
antigen specific CD4+ and CD8+ T cells secreting IFN- γ was 
increased only in Np and Gn immunized mice after antigen 
stimulation compared them to unstimulated T cells (Part Ⅱ, Fig 
11D).
  Next, to assess the protective ability of the single SFTSV 
subunit vaccine against a lethal dose of SFTSV, 103 FFU SFTSV 
were tested on mice vaccinated with a single SFTSV subunit (Np, 
Gn, and Gc) and control (PBS or Fc fragment) with alum adjuvant 
(Part Ⅱ, Fig 12). All vaccinated groups had been monitored for 
survival rate and body weight change until the recovery of the 
surviving mice after the challenge (Part Ⅱ, Fig 12A and B). After 
virus infection, all mice from control (PBS), control (Fc), and 
Gc-Fc groups were dead on 5, 6, and 8 day post-infection, 
respectively. However, 60% (3 of 5) of the Np-His immunized 
mice survived and 50% (2 of 4) of the Gn-Fc immunized mice 
survived (Part Ⅱ, Fig 12A). PBS, Fc, and Gc-Fc with alum 
immunized animals significantly lost weight until death, whereas 
surviving mice vaccinated with NP lost weight until reaching 81% 
of their original weight on 7 day post-infection, and mice 
immunized with Gn-Fc lost weight until reaching 80% of their 
original weight on 8 day post-infection, then both gradually 




Figure 11. Antibody and T cell immune response of recombinant
SFTSV single subunit vaccine against viruses.
(A) A schematic schedule of single subunit immunization and SFTSV
challenge. 10 μg of single subunit of SFTSV with 100 μg of Alum
adjuvant were immunized to the IFNAR K/O C57BL/6 mice. Four
mice were used for Ctrl(Fc), Gn, and Gc-Fc and five mice were used
for Ctrl(PBS), and Np-His groups. Total three times immunization
interval two weeks, then, immunological analysis and challenge of 103
FFU viruses were conducted at a week and two weeks after the
third immunization, respectively. (B) Anti-specific antigens (Fc, Np,
Gn, or Gc) IgG response was monitored by ELISA at a week after
the third immunization. The antibody titers of anti-Fc, Np, Gn, or Gc
IgG in sera of mice (n=5) vaccinated with each subunit vaccine are
presented. Cut-off titers (mean O.D. + 3x S.D. at 1:100 diluents) were
measured using sera from Ctrl(PBS) immunized mice. IgG titers of
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ctrl(PBS) serum was determined against Np, Gn, and Gc proteins. (C)
The neutralizing antibody titration (FRNT50) against SFTSV was
measured by sera from Ctrl(PBS), Fc, Np, Gn, or Gc immunized mice
(n=5) before virus challenge. Each serum was serially diluted from
1:100 to 1:25,600 and FRNT50 was performed in 24-well plates. (D)
Splenocytes were collected from mice immunized with each
recombinant SFTSV antigen (Ctrl(PBS), Np, GN, or Gc) at a week
after the third immunization. Antigen dependent production of IFN-γ,
TNF-α, and double-positive by CD4+ T (left panel) or CD8+ T cells
(right panel) were evaluated using flow cytometry after stimulation
with the indicated antigens. Data are shown as mean ± S.D. from
duplicate assays with five mice per group. *, p < 0.05; **, p < 0.01;
***, p < 0.001.
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Figure 12. Survival and body weight change of IFNAR K/O mice
vaccinated SFTSV single subunit against a lethal dose of SFTSV.
(A and B) Survival curves and body weight chagne of immunized
IFNAR K/O mice after lethal challenge with SFTSV. Their survival
rate and body weight change were monitored until all surviving mice
recovered from the disease. **, p< 0.01 when compared with
non-immunized group (PBS).
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Protection of mixed subunits vaccine against a
lethal dose of SFTSV in IFNAR K/O mice.
To assess the antibody dependent immune response in IFNAR 
K/O mice immunized with a mixed SFTSV subunit vaccine (Gc+Np 
(GNP), Gc+Np (GcP), and Gc+Gc+Np (NCP)), the titer of 
antigen-specific antibodies and neutralizing antibodies was 
examined (Part Ⅱ, Fig 13B). Vaccination with the mixed SFTSV 
subunits with alum adjuvant significantly increased the titer of 
antigen-specific antibodies against immunized antigens (Np, Gn, 
and Gc) in IFNAR K/O mice. Especially, the titer of the anti-Np 
specific IgG in GcP (mean ± S.D. = 1.1x107 ± 1.3x107, n=7) 
group was approximately two hundred times higher than the titer 
of those in the GNP (mean ± S.D. = 4.3x104 ± 4.1x104, n=7) and 
NCP (mean ± S.D. = 4.8x104 ± 3.7x104, n=7) groups. The 
FRNT50 titer of mice vaccinated with NCP was highest (mean ± 
S.D. = 678.4 ± 1268, n=7), though the individual titer of NCP had 
a variation, while the titers of GNP (mean ± S.D. = 143.7 ± 
185.4, n=7) and GcP (mean ± S.D. = 143.5 ± 118.2, n=7) were 
similar to each other. 
  To characterize the T cell-mediated immune response in the 
IFNAR K/O mice vaccinated with the recombinant mixed SFTSV 
subunits, antigen-specific CD4+ and CD8+ T cell responses 
producing IFN- γ and TNF-α in the spleen of immunized mice 
were evaluated by flow cytometry (Part Ⅱ, Fig 13D). The 
percentage of antigen specific TNF-α secreting CD4+ and CD8+ T 
cells stimulated with immunized antigens for all immunized groups 
was dramatically expanded compared to those with unstimulated 
cells. And the frequency of IFN- γ and TNF-α double positive 
cells was significantly low for all vaccinated groups. Interestingly, 
- 66 -
the percentage of Np specific IFN- γ secreting CD4+ and CD8+ T 
cells increased in all mixed vaccine groups compared to those 
with Gn or Gc antigen-stimulated cells. Noticeably, the frequency 
of NP dependent IFN- γ producing CD4+ and CD8+ T cells in the 
GcP group significantly increased compared to those of other 
groups (GNP and NCP) (Part Ⅱ, Fig 13D).
  The protective effect of the mixed subunits vaccines against 
SFTSV was further investigated in vivo by challenging mice with 
103 FFU SFTSV (Part Ⅱ, Fig 14). All vaccinated groups (Gn+NP 
(GNP), Gc+NP (GcP), and Gn+Gc+NP (NCP)) had been monitored 
for survival rate and body weight change until the recovery of 
the surviving mice after the virus challenge (Part Ⅱ, Fig 14A and 
B). All of the control (PBS) immunized mice died by 6 day 
post-infection (dpi). On the other hand, around 70% (5 of 7) of 
GNP, 86% (6 of 7) of GcP, and 57% (4 of 7) of NCP immunized 
mice survived (Part Ⅱ, Fig 14A). PBS with alum adjuvant 
immunized animals rapidly decreased in weight until death. 
However, surviving mice with the immunizations of GNP, GcP, and 
NCP lost weight until reaching 86%, 89%, and 82% of their 
original body weight on 7, 7, and 8 day post-infection (dpi), 




Figure 13. Antibody and T cell immune response of recombinant
SFTSV mixed subunits vaccine against viruses.
(A) A schematic schedule of mixed subunits immunization and
SFTSV challenge. 10 μg of each subunit used for mixed vaccines
with 100 μg of Alum adjuvant were immunized to the IFNAR K/O
C57BL/6 mice (n=7 per group). Three times vaccination interval two
weeks, then, immunological analysis and challenge of 103 FFU viruses
were conducted at a week and two weeks after the third
immunization, respectively. (B) Anti-specific antigens (Np, Gn, or Gc)
IgG response in each mixed vaccine group was monitored by ELISA
at a week after the third immunization. The antibody titers of
anti-Np, Gn, or Gc IgG in sera of mice (n=7) vaccinated with each of
mixed subunits vaccine are presented. Cut-off titers (mean O.D. + 3x
S.D. at 1:100 diluents) were measured using sera from Ctrl(PBS)
immunized mice. IgG titers of ctrl(PBS) serum was determined
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against Np, Gn, and Gc proteins. The asterisks indicate significance
compared to the respective control(NP), control(Gn), and cotrol(Gc).
(C) The neutralizing antibody titration (FRNT50) against SFTSV was
measured by sera from Ctrl(PBS), GNP, GcP, and NCP immunized
mice (n=7) before virus challenge. Each serum was serially diluted
from 1:100 to 1:25,600 and FRNT50 was performed in 24-well plates.
(D) Splenocytes were collected from mice immunized with each
recombinant SFTSV antigens (Ctrl(PBS), GNP, GcP, or NCP) at a
week after the third immunization. Antigen specific production of
IFN-γ, TNF-α, and double-positive by CD4+ T (left panel) or CD8+
T cells (right panel) were evaluated using flow cytometry after
stimulation with the indicated antigens. Data are shown as mean ±
S.D. from duplicate assays with five mice per group.*, p < 0.05; **,
p < 0.01, *** p < 0.0003; ****, p < 0.0001.
- 71 -
Figure 14. Survival and body weight change of IFNAR K/O mice
vaccinated SFTSV mixed subunits against a lethal dose of SFTSV.
(A and B) Survival curves and body weight change of immunized
mice after lethal challenge with SFTSV. Their survival rate and body
weight change was monitored until all surviving mice recovered from




SFTSV which is an emerging virus has mainly been distributed
throughout eastern Asian countries: South Korea [16], China [14], and
Japan [19]. SFTS cases have been also reported in other Asian
countries: Vietnam [17] and North Korea [8, 23], indicating that
SFTSV has gradually been spreading through the world. The mean
mortality of SFTS cases in three countries (South Korea, China, and
Japan) is approximately 5-27% [18, 52, 53]. Due to the increasing
number of SFTS cases and mortality, several research groups have
studied in order to develop vaccines protecting against SFTSV.
According to Kim K.H. et al. report, recovered SFTS patients’
SFTSV glycoprotein N-specific antibodies might be used for therapies
or vaccines against a lethal dose of SFTSV in IFNAR1 K/O mice.
Gn-specific antibodies have a neutralizing effect on SFTSV in vitro
and offer complete protection in immuno-compromised mice [3]. DNA
vaccines encoding the full length of SFTSV Gn, Gc, N, NS, and
RdRp genes were also developed in the ferret model [26]. These
vaccines have a high FRNT50 titer against SFTSV and may elicit a
robust T cell response secreting IFN- γ about five SFTSV antigens
in ferrets as well as evoke long-lasting CD8+ T cells. With these
immunological responses, this DNA vaccine successfully confers
perfect protection in the old ferret model (>4 years). Furthermore, the
transfer of sera from Gn and Gc plasmid immunized ferrets provides
complete protection after challenging SFTSV [26]. The vaccination of
recombinant SFTSV nonstructural proteins (NS) could elicit strong
anti-Ns specific antibodies, but all mice immunized with rSFTSV NS
proteins were dead with a high number of viruses in the serum,
liver, spleen, and kidneys [28]. Another research team suggested that
recombinant viruses encoding the SFTSV glycoprotein N&C gave
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100% protection against lethal challenge and have neutralizing
antibodies (titer of FRNT50: 1:500) [27].
As seen in many vaccine studies about SFTSV, the animals
relatively close to humans were considered a good standard animal
model for infectious diseases [64]. Among many animal models, the
mice have been used for study of various infectious pathogens
because the immune systems of mice and humans are very similar
[65]. Unfortunately, wild mice are not susceptible to many other
pathogens, so IFN receptor knock out mice were a great alternative
for vaccine study. Type I IFN receptor knock out mice were created
in 1994 [66]. This transgenic mice challenged with Semliki Forest
virus, Vesicular stomatitis virus, or vaccinia virus showed increased
susceptibility resulting in high viral load in organs and death at
lower challenge doses compared to wild-type mice. Among
Bunyaviridae order, type I IFN K/O mice were generally used for
Crimean-Congo hemorrhagic fever virus (CCHFV) [67, 68], Severe
fever with thrombocytopenia virus (SFTSV) [69, 70] infectious
disease study.
Even though there are issues with DNA vaccines inducing tumors
or autoimmune diseases [54], DNA vaccines could produce a natural
form of antigens that trigger innate and adaptive immune responses
[33]. Here, I demonstrate that DNA vaccines encoding SFTSV
Np-NS, Gn, and Gc fused with Flt3L at N-terminus and IL-12
cytokine could stimulate IFN-γ secreting lymphoid cells and then
confer complete protection in IFNAR K/O mice against a lethal
SFTSV challenge (Part Ⅰ, Fig 4A). The increased frequency of IFN-
γ secreting CD4+ and CD8+ T cells from pSFTSV-IL12 vaccination
under SFTSV NP and Gn antigens may be because of an IL-12
cytokine response for adjuvant (Part Ⅰ, Fig 3D) [40, 55]. The viral
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copy numbers and platelet counts of both pSFTSV and
pSFTSV-IL-12 vaccines were similar with the mock vector plasmid
immunization and lower than the uninfected group at the early stage
of infection, respectively (Part Ⅰ, Fig 4B). As shown in Part Ⅰ, Fig
3A and B, pSFTSV and pSFTSV-IL12 DNA vaccines elicited a lower
antigen-specific antibody production, besides, neutralizing antibody
titer was low. Early-stage viremia and thrombocytopenia may be
correlated with humoral immune responses [26, 56]. Especially, as
shown by Kwak J.E. et al. report, the formation of antibodies against
SFTSV glycoprotein Gn and Gc may be important to block viremia
and thrombocytopenia [26]. For these reasons, I speculated the reason
of failure to reduce increasing SFTSV at an early stage was due to
extremely low SFTSV Gn and Gc antibodies (data not shown).
SFTSV subunit vaccines with a single subunit or multiple mixed
subunits were also evaluated. Subunit vaccines have generally been
used for vaccine studies because of low production costs and
increasing biosafety [32]. Four kinds of recombinant SFTSV subunits
(SFTSV Np-His, Gn-Fc, and Gc-Fc) were prepared. The human IgG
Fc domain in recombinant proteins allows the formation of
dimerization to increase avidity and increases plasma half-life using
neonatal Fc receptor (FcRn) [1, 57, 58], furthermore, human IgG Fc
domain can interact with murine FcγR [59]. For these reasons, Fc
proteins have been used for many vaccine studies and this vaccine
study [60-62]. 60% (3 of 5) of mice vaccinated with recombinant
SFTSV Np and 50% (2 of 4) of mice immunized with recombinant
SFTSV Gn proteins survived against a lethal dose of SFTSV.
SFTSV Gc protein vaccination could extend the life of mice until 8
day post-infection (dpi) (Part Ⅱ, Fig 12A). Antigen-specific IgG and
FRNT50 titer of all single subunit vaccine groups was higher than
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that of DNA vaccines (Part Ⅱ, Fig 11B). Interestingly, FRNT50 titer
of the Gc immunized group was higher than the Np and Gn groups,
though all of the Gc subunit vaccinated mice were dead. The titer is
similar with the FRNT50 titer of rVSV encoding SFTSV glycoproteins
vaccine that confers complete protection against a SFTSV lethal
challenge [27]. Also, as shown in body weight change, the body
weight of the Gc vaccination group started to decrease from 4 day
post-infection (dpi) even though those of the other groups started to
decrease from day 2 or 3 (Part Ⅱ, Fig 12B), indicating that anti-Gc
specific antibodies may have a strong neutralizing effect against
SFTSV at an early infection period. However, the percentage of
antigen specific IFN-γ producing CD4+ and CD8+ T cells of mice
immunized with Gc proteins did not increase. Only those of mice
vaccinated with NP or Gn proteins were elevated (Part Ⅱ, Fig11D). I
speculated that NP or Gn proteins would be a strong factor for
stimulating antigen specific IFN-γ producing CD4+ and CD8+ T cells
which may be important for protection against SFTSV. Furthermore,
SFTSV Gc immunization could make neutralizing antibodies for
SFTSV that may prolong the life expectancy of IFNAR K/O mice.
To develop a strong protective vaccine against SFTSV, I tried to
use mixed SFTSV subunits (Gn+NP (GNP), Gc+NP (GcP), and
Gn+Gc+NP (NCP)) for the vaccination of IFNAR K/O mice based on
single protein vaccine data. 70% (5 of 7) of mice of GNP, 86% (6 of
7) of mice of GcP, and 57% (4 of 7) of mice of NCP groups survived
more than the single subunits Np (60%) and Gn (50%) of the vaccine
groups (Part Ⅱ, Fig 14A). The GcP group triggered a high level of
anti-NP specific antibody titer and the neutralizing antibody titer
(FRNT50) was similar with the single subunit Gn vaccine group (Part
Ⅱ, Fig 13B, and C). These results showed anti-Np specific antibody
- 76 -
titer and neutralizing titer (FRNT50) of serum from the GcP
vaccinated mice was significantly higher than that of the
pSFTSV-IL12 vaccine (Part Ⅰ, Fig 3A and B, Part Ⅱ, Fig 13B and
C). Antigen specific TNF-α secreting CD4+ and CD8+ T cells in all
mixed subunit groups were significantly increased compared to all
groups with a single protein vaccination. In addition, the percentage
of IFN-γ secreting both CD4+ and CD8+ T cells against N proteins
in the GcP immunized mice was more increased than those of other
groups (GNP and NCP) (Part Ⅱ, Fig 13D). However, the percentage
of IFN-γ secreting CD4+ T cell was about two times lower than that
of pSFTSV-IL12 vaccinated mice (Part Ⅰ, Fig 3D, Part Ⅱ, Fig 13D).
Taken together, I found that DNA vaccine confers complete protection
by enhancing T cell immune response against SFTSV, however, this
vaccine has the limitation of low titer of Ag-specific antibodies and
neutralizing antibodies. Recombinant SFTSV Np and Gn provide
marginally increased CD4+ T cell immune response and an
approximately 50% survival rate against a lethal dose of SFTSV.
However, the serum of recombinant Gc subunit vaccinated mice has a
strong neutralizing effect against SFTSV. Mixed Gc and Np (GcP)
subunit vaccinations elevated the neutralizing effect against SFTSV
even though CD4+ T cell response was slightly increased. Besides,
approximately 90% of GcP vaccinated mice survived against a lethal
dose of SFTSV. While pSFTSV-IL12 DNA vaccine presents a high
level of antigen specific IFN-γ secreting T cells, it has a poor
antibody dependent immune response. On the other hand, the Gc+Np
(GcP) subunit vaccine provides great antibody dependent immune
response despite increasing T cell immunity a bit. Generally, the
disadvantage of DNA vaccines is a weak immune response in human
trials [63] and they may induce tumors or autoimmune diseases [54].
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A subunit vaccine has the defect of low T cell response induction
and low immunogenicity. Consistently, in this study, the
pSFTSV-IL12 DNA vaccine elicited a high antigen specific IFN-γ 
secreting T cell response and the GcP subunit vaccine provided a
high antibody dependent immune response. So, a DNA prime/protein
boost vaccine may be the new direction of the SFTSV vaccine as it
increases both T cell and antibody dependent immunity with biosafety
[71-73]. Further studies on pSFTSV-IL12 DNA prime/GcP subunit
boost vaccine evaluation and understanding mechanism of
immunological pathogenesis in mice and higher animals should be
followed to develop the perfect SFTSV vaccine.
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국문 초록
중증열성혈소판감소증 바이러스(SFTSV)는 한국, 중국, 일본등지에서 중
증열성혈소판감소증을 일으키는 진드기 매개 바이러스로, 최근 대만과
베트남 등 동남아시아 지역에서도 발생이 보고되고 있다. 이 바이러스
감염증은 인간에서 5-27%의 높은 치사율을 보이고 있으나, 효과적인 바
이러스 백신이나 치료제는 아직 없다. 본 연구에서는 SFTSV에 대한 백
신을 개발하기 위하여 DNA 백신과 아단위 백신의 효능을 검증하는 실
험을 수행하였다. 먼저 SFTSV의 구조 단백질인 Gn 과 Gc 그리고
Np-NS 융합 단백질을 암호화하는 유전자들과 인터루킨-12 (IL-12)를
발현할 수 있는 DNA plasmid를 백신 후보물질로 선정하여 제1형 인터
페론 수용체 돌연변이(IFNAR K/O) 마우스에 면역하고, 치사량의
SFTSV를 감염시켰을 때, 치사율과 증상 유무를 조사하였다. 이 DNA
백신이 투여된 쥐는 치사량의 SFTSV 감염에 대해 100% 보호되는 것을
확인하였다. 이 DNA 백신이 바이러스에 대한 중화 능력을 유도하지는
못하였으나, 항원 특이적인 T 세포 반응을 유의하게 유도하는 것으로 보
아 세포 매개 면역반응이 보호능을 제공하고 있음을 알 수 있었다. 다음
으로 SFTSV의 구조 단백질들(Np, Gn, 그리고 Gc)을 각각 대장균과 진
핵세포에서 발현/정제하고, 이를 아단위 백신으로 사용하여 그 효과를
시험하였다. 개별 아단위 면역시험에서는 NP와 Gn 면역그룹에서 치사량
감염에 대해 약 50% 이상의 보호 효과를 나타내었으나, Gc 재조합 단백
질을 면역한 생쥐들은 모두 사망하였다. SFTSV의 NP 단백질은 바이러
스에 대한 세포 매개성 면역반응을 잘 유도하였으며, Gc 단백질은 체액
성 면역반응을 유의하게 증가시키는 것으로 확인되었다. 마지막으로,
IFNAR K/O 생쥐들에게 재조합 항원들을 혼합하여 면역을 하고 백신의
효능을 분석한 결과(Gn+NP, Gc+NP, 그리고 Gn+Gc+NP), Gc+NP 면역
그룹은 치사량의 SFTSV 감염에 대하여 약 90%의 생존율을 보였으며,
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유의한 T 세포 반응과 바이러스 중화항체 증가가 관찰되었다. Gn+NP
그리고 Gn+Gc+NP 면역 그룹은 각각 70%와 57%의 생존율이 관찰되어
Gc+NP 그룹이 가장 좋은 백신 효능을 보였다. 이 결과들을 종합하였을
때, SFTSV의 유전자들을 암호화하는 DNA 백신이나 그 구조 단백질들
의 조합을 면역하는 백신 방법은 세포매개 면역반응 또는 중화항체 생성
을 통해 중증열성혈소판감소증에 대한 보호 면역반응을 제공할 수 있다
는 것을 확인하였으며, 이를 통해 SFTS의 백신 개발에 활용될 수 있을
것으로 판단된다.
본 내용은 폴로스 열대 질환 (Kang, J. G., Jeon, K., Choi, H., Kim, Y.,
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plasmid DNA encoding IL-12 and antigens of severe fever with
thrombocytopenia syndrome virus elicits complete protection in IFNAR
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판 완료된 내용임.
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